COL4A5基因错义变异p.(Gly624Asp)年轻Alport综合征患者治疗的终身效果:一项前瞻性队列研究
该前瞻性观察性队列研究(NCT02378805)纳入114例携带相同COL4A5基因变异p.(Gly624Asp)的个体,以终末期肾衰竭年龄和预期寿命为终点,评估早期ACEi干预的肾脏保护作用。结果显示未治疗半合子患者均进展至终末期肾衰竭,而早期治疗(eGFR≥60 mL/min/1.73 m2)的半合子患者均存活且未达终末期肾衰竭,提示早期治疗可能将肾衰竭延迟至终生。
要点
- 13例未治疗半合子患者全部进展至终末期肾衰竭,平均年龄48.9±13.7岁。
- 28例早期治疗(eGFR≥60 mL/min/1.73 m2)半合子患者均存活且未达终末期肾衰竭。
- 65例杂合子中4例未治疗者发生终末期肾衰竭,治疗者无一发生。
核心结论
- 在Alport综合征中,对携带错义变异的个体进行早期治疗可能将肾衰竭延迟至终生,从而改善预期寿命和生活质量且无需肾脏替代治疗。
- 部分治疗患者已达退休年龄而肾功能仍正常,其未治疗亲属在相同或更小年龄已进展至终末期肾衰竭。
- 对肾小球性血尿儿童早期检测Alport相关基因变异可能有助于及时进行肾脏保护性干预。
研究设计与样本
- 前瞻性观察性队列研究(NCT02378805),纳入114例携带相同COL4A5基因变异p.(Gly624Asp)的个体。
- 以终末期肾衰竭年龄和预期寿命为终点,与治疗情况做相关性分析。
主要发现
- 13例未治疗半合子患者全部进展至终末期肾衰竭,平均年龄48.9±13.7岁;3例极晚治疗半合子患者亦进展至终末期肾衰竭,平均年龄51.7±4.2岁;平均预期寿命59.2±9.6岁。
- 28例早期治疗(eGFR≥60 mL/min/1.73 m2)半合子患者均存活且仍未达终末期肾衰竭,其年eGFR下降幅度与健康个体相似。
- 65例杂合子中,4例未治疗个体在53.3±20.7岁时发生终末期肾衰竭;接受治疗的杂合子女性无一发生终末期肾衰竭。
临床怎么用
- 作者认为,对肾小球性血尿儿童早期检测Alport相关基因变异可能有助于及时进行肾脏保护性干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEis) have evolved as a first-line therapy for delaying end-stage renal failure (ESRF) in Alport syndrome (AS). The present study tested the hypothesis of a superior nephroprotective potential of an early ACEi intervention, examining a cohort with the COL4A5 missense variant p.(Gly624Asp). METHODS: In this observational cohort study (NCT02378805), 114 individuals with the identical gene variant were explored for age at ESRF and life expectancy in correlation with treatment as endpoints. RESULTS: All 13 untreated hemizygous patients developed ESRF (mean age 48.9 ± 13.7 years), as did 3 very late treated hemizygotes (51.7 ± 4.2 years), with a mean life expectancy of 59.2 ± 9.6 years. All 28 earlier-treated [estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2] hemizygous patients were still alive and still had not reached ESRF. Therapy minimized the annual loss of their GFR, similar to the annual loss in healthy individuals. Of 65 heterozygotes, 4 untreated individuals developed ESRF at an age of 53.3 ± 20.7 years. None of the treated heterozygous females developed ESRF. CONCLUSIONS: For the first time, this study shows that in AS, early therapy in individuals with missense variants might have the potential to delay renal failure for their lifetime and thus to improve life expectancy and quality of life without the need for renal replacement therapy. Some treated patients have reached their retirement age with still-functioning kidneys, whereas their untreated relatives have reached ESRF at the same or a younger age. Thus, in children with glomerular haematuria, early testing for Alport-related gene variants could lead to timely nephroprotective intervention.
引用
- Boeckhaus J, Hoefele J, Riedhammer KM, et al. Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study. Nephrol Dial Transplant. 2022. PMID: 35022790. doi:10.1093/ndt/gfac006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。